TY - JOUR
T1 - AMC 048
T2 - Modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma
AU - AIDS Malignancy Consortium
AU - Noy, Ariela
AU - Lee, Jeannette Y.
AU - Cesarman, Ethel
AU - Ambinder, Richard
AU - Baiocchi, Robert
AU - Reid, Erin
AU - Ratner, Lee
AU - Wagner-Johnston, Nina
AU - Kaplan, Lawrence
N1 - Publisher Copyright:
© 2015 by The American Society of Hematology.
PY - 2015/7/9
Y1 - 2015/7/9
N2 - The toxicity of dose-intensive regimens used for Burkitt lymphoma prompted modification of cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for HIV-positive patients. We added rituximab, reduced and/or rescheduled cyclophosphamide and methotrexate, capped vincristine, and used combination intrathecal chemotherapy. Antibiotic prophylaxis and growth factor support were required; highly active antiretroviral therapy (HAART) was discretionary. Thirteen AIDS Malignancy Consortium centers enrolled 34 patients from 2007 to 2010.
AB - The toxicity of dose-intensive regimens used for Burkitt lymphoma prompted modification of cyclophosphamide, vincristine, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for HIV-positive patients. We added rituximab, reduced and/or rescheduled cyclophosphamide and methotrexate, capped vincristine, and used combination intrathecal chemotherapy. Antibiotic prophylaxis and growth factor support were required; highly active antiretroviral therapy (HAART) was discretionary. Thirteen AIDS Malignancy Consortium centers enrolled 34 patients from 2007 to 2010.
UR - http://www.scopus.com/inward/record.url?scp=84937779319&partnerID=8YFLogxK
U2 - 10.1182/blood-2015-01-623900
DO - 10.1182/blood-2015-01-623900
M3 - Article
C2 - 25957391
AN - SCOPUS:84937779319
SN - 0006-4971
VL - 126
SP - 160
EP - 166
JO - Blood
JF - Blood
IS - 2
ER -